AcelRx Pharmaceuticals now has a consensus rating of Hold and a consensus price target of $7.83. AcelRx Pharmaceuticals had 17 analyst reports since August 4, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co on Tuesday, August 4 with "Hold". Over the same time span, the stock marked US$5.75 as its best level and the lowest price reached was US$1.95.
Jefferies Group LLC lowered shares of AcelRx Pharmaceuticals, Inc. The firm has "Buy" rating given on Friday, August 25 by RBC Capital Markets. The company presently has an average rating of Hold and an average price target of $7.83.
10/03/2017 - H.C. Wainwright began new coverage on AcelRx Pharmaceuticals, Inc. giving the company a "buy" rating. TH Capital has "Buy" rating and $15 target. ASH's SI was 2.40 million shares in October as released by FINRA. The shares were sold at an average price of $5.29, for a total value of $53,751.69. The SI to Ashland Incorporated's float is 3.89%. CytRx Corporation (CYTR) has declined 78.08% since October 14, 2016 and is downtrending. The difference between the expected and actual EPS was $-0.01/share, which represents an Earnings surprise of -3.6%. Its book value per share for the most recent quarter is $-0.7 while its price to book ratio for the same period is 0, as for as the company's cash per share for the most recent quarter is $0, however its price to cash per share ratio for the same period is 0.
The Average Earnings Estimate for the Current Fiscal quarter is $-0.25 per share, according to consensus of 6 analysts.
AcelRx Pharmaceuticals, Inc.is a pharmaceutical firm focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. Piper Jaffray Companies set a $3.00 price target on AcelRx Pharmaceuticals and gave the company a hold rating in a research note on Tuesday, July 25th. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Losses We also note that ACRX has negative GAAP earnings in the past year which makes it ever more susceptible to stock volatility. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. The stock had previously closed at ($2.10), but opened at $0.00. AcelRx Pharmaceuticals shares last traded at $0.00, with a volume of 24231300 shares. Teachers Advisors LLC grew its holdings in AcelRx Pharmaceuticals by 14.6% in the fourth quarter. It has underperformed by 2.41% the S&P500.
Investors sentiment decreased to 0.75 in 2017 Q2. Its down 0.25, from 1 in 2017Q1. ValuEngine upgraded shares of AcelRx Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Tuesday, September 26th. 11 funds opened positions while 13 raised stakes. Salem Investment Counselors owns 3,435 shares. Royal National Bank & Trust Of Canada owns 10,182 shares for 0% of their portfolio. Bancorporation Of America Corp De reported 14,964 shares. Wealthtrust Axiom Ltd Liability Corp reported 210,000 shares.
According to analysts Acelrx Pharmaceutica (NASDAQ:ACRX)'s minimum EPS for the current quarter is at $-0.3 and can go high up to $-0.22. This reality, in and of itself, makes ACRX susceptible to excessive risk as the stock may vascillate based on drug trial results, FDA decisions, new government pricing rules, and especially takeover rumors. Da Davidson And Com, Montana-based fund reported 61,900 shares. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/14/acelrx-pharmaceuticals-inc-acrx-rating-reiterated-by-hc-wainwright.html. 11,916 were reported by Guggenheim Capital Ltd. State Street owns 319,133 shares. Market capitalization is calculated by multiplying a company's shares outstanding by the current market price of one share. Creative Planning stated it has 17,700 shares or 0% of all its holdings. Renaissance Tech Ltd Co accumulated 0% or 250,500 shares.
In terms of Buy, Sell or Hold recommendations, Acelrx Pharmaceutica (NASDAQ:ACRX) has analysts' mean recommendation of 2.2. The firm earned "Buy" rating on Wednesday, August 2 by Roth Capital. TheStreet downgraded Ashland Global Holdings Inc. The mean rating score for this stock is at 1.00.